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ABSTRACT
Cathepsins S (CatS) has been implicated in numerous tumourigenic processes 
and here we document for the first time its involvement in CCL2 regulation within 
the tumour microenvironment. Analysis of syngeneic tumours highlighted reduced 
infiltrating macrophages in CatS depleted tumours. Interrogation of tumours and 
serum revealed genetic ablation of CatS leads to the depletion of several pro-
inflammatory chemokines, most notably, CCL2. This observation was validated in vitro, 
where shRNA depletion of CatS resulted in reduced CCL2 expression. This regulation 
is transcriptionally mediated, as evident from RT-PCR analysis and CCL2 promoter 
studies. We revealed that CatS regulation of CCL2 is modulated through CD74 (also 
known as the invariant chain), a known substrate of CatS and a mediator of NFkB 
activity. Furthermore, CatS and CCL2 show a strong clinical correlation in brain, breast 
and colon tumours. In summary, these results highlight a novel mechanism by which 
CatS controls CCL2, which may present a useful pharmacodynamic marker for CatS 
inhibition.
INTRODUCTION
Unraveling the complexity of interactions within 
the microenvironment has become a major focus of 
biomedical research within recent years. Cellular 
communications are critical mediators of numerous 
diseases including fibrosis, myelodysplasia and cancer, 
where normal cells such as immune cells are recruited 
and/or reprogrammed to promote disease progression.
CatS is a lysosomal cysteine protease, the 
expression of which has been associated with a number 
of inflammatory diseases including rheumatoid arthritis, 
atherosclerosis and cancer. CatS expression has been 
shown to be elevated within tissues from these conditions, 
with genetic ablation or therapeutic targeting strategies 
diminishing disease severity and/or progression [1–4]. We 
have previously shown that CatS expression is associated 
with a number of malignancies including astrocytomas 
and colorectal carcinomas, and that depletion of CatS 
can result in the attenuation of tumourigenesis [5–8]. 
Using therapeutic targeting strategies, we have identified 
that CatS is a key mediator of tumour invasion and 
angiogenesis in tumourigenesis [6, 9, 10].
Recent studies have interrogated the impact of 
CatS with regards to the tumour microenvironment. We 
have previously examined the contribution of tumour-
derived and microenvironment-derived CatS to colorectal 
tumourigenesis using a stratified depletion approach. We 
identified that tumour-derived and microenvironment-
derived CatS both have significant roles to play in 
facilitating tumour growth, through proliferation, 
apoptosis and angiogenesis [8]. Furthermore, the 
importance of macrophage-derived CatS has also been 
examined, with studies demonstrating its contribution 
in murine tumour model growth, and more recently in 
mediating breast-to-brain metastasis [11, 12].
Oncotarget2www.impactjournals.com/oncotarget
Extensive work has been carried out to identify 
protease substrates in order to elucidate protease-specific 
roles within biological processes. Previous studies have 
identified multiple CatS substrates such as the angiogenic 
proteins laminin, arresten, canstatin and endostatin 
[13, 14]. In this investigation, we examined a possible 
role of CatS in the regulation of tumourigenic factors. 
By utilizing commercial antibody arrays, we performed 
medium throughput, focused screens of tumourigenic 
proteins in order to identify those exhibiting altered 
expression due to CatS depletion in murine models and 
cell lines. We have ascertained that CatS can regulate 
the expression of several pro-tumourigenic factors, most 
notably the pro-inflammatory chemokine, CCL2. We 
showed that this regulation appears to occur through 
CatS cleavage of CD74, which in turn transcriptionally 
regulates CCL2 expression, through the activation of 
NFkB. Interrogation of patient microarray datasets 
has confirmed the clinical correlation between CatS 
and CCL2, highlighting physiological significance and 
suggests that CCL2 may be a potential biomarker of CatS 
activity within disease.
RESULTS
CatS alters stromal cell migration
We have previously shown that tumour-derived 
CatS is important for the growth of tumours in vivo 
[8]. In this current study we wished to interrogate in 
more depth the impact of tumour-derived CatS on the 
tumour microenvironment. MC38 colon carcinoma cells 
expressing non-targeting control (NT) and CatS shRNA 
constructs (Supplementary Fig. 1) were grown in wild type 
C57BL/6 mice and macrophage infiltration was examined 
by flow cytometry. Whilst tumour cells lacking CatS grew 
more slowly than control cells expressing the protease, in 
agreement with our previous findings (Fig. 1a), a difference 
in infiltrating macrophages was difficult to interrogate by 
flow cytometry due to the small but highly encapsulated 
nature of these tumours (data not shown). Therefore, we 
examined the impact of CatS on an alternative syngeneic 
model using LLC lung carcinoma tumour cells, generated 
to express non-targeting control and CatS targeting shRNA 
constructs (Supplementary Fig. 2). In agreement with our 
MC38 model, diminished CatS levels in the LLC cells 
attenuated tumour growth (Fig. 1b). Subsequent analysis by 
flow cytometry revealed a marked reduction in macrophage 
infiltration to the tumour (29% reduction) (Fig. 1c).
We then wanted to determine if this effect was 
preserved in vitro, and if this reduced infiltration 
observed in the complex cellular milieu of the tumour 
microenvironment was a consequence of specific CatS 
depletion in the tumour cells. Therefore, conditioned 
media was harvested from non-targeting control and CatS 
shRNA expressing cells, and used as a chemoattractant in 
in vitro migration assays using murine monocyte-derived 
macrophages. Macrophage migration was significantly 
impaired when conditioned media collected from CatS 
shRNA expressing cells (in both MC38 and LLC cell line 
models) was used as a chemoattractant in comparison 
to controls (Fig. 1d, 1e). We also examined fibroblast 
migration and found that this too was significantly 
diminished when CatS shRNA conditioned media was 
used as a chemoattractant (Fig. 1f).
CatS controls expression of  
pro-inflammatory chemokines and fibroblast 
chemoattractant proteins
The observation that CatS depletion can attenuate 
macrophage and fibroblast migration, has revealed a novel 
and uncharacterized role for CatS in tumourigenesis. 
We have previously observed the altered expression of 
angiogenic proteins such as FGF in CatS depleted tumours 
[8]. In order to elucidate the mechanism by which CatS 
mediates cellular recruitment, we decided to examine 
changes in protein expression using commercially available 
antibody arrays. This allowed us to interrogate if any 
factors implicated in macrophage recruitment or fibroblast 
migration were altered as a result of CatS ablation. Antibody 
array analysis of protein lysates extracted from the MC38 
tumours, identified several proteins deregulated as a result of 
CatS repression. In particular, the absence of CatS correlated 
with a reduction in several pro-inflammatory chemokines 
such as CXCL10, CXCL1 and in particular, CCL2 (Fig. 2a, 
2b). Interrogation of this data also revealed the deregulation 
of multiple chemokines that have been postulated to be 
fibroblast chemoattractants, including TGFβ, previously 
associated with CatS and fibroblasts in myocardial 
infarctions [15] (Supplementary Fig. 3). Furthermore, 
analysis of serum samples from MC38 tumour bearing mice 
also revealed a notable reduction in CCL2 levels, whereas 
serum levels of CXCL10 and CXCL1 were unaffected 
(Fig. 2c, 2d).
CatS regulates the expression of the  
pro-inflammatory chemokine CCL2
In order to validate results obtained in the antibody 
array, MC38 and LLC CatS shRNA cells were subjected 
to analysis in vitro. Interrogation of both cell lysates and 
supernatants revealed that CCL2 expression levels were 
significantly reduced when CatS expression was depleted 
by shRNA (Fig. 3a–3d). By observing altered expression of 
both intracellular and extracellular CCL2, this suggested that 
CatS was not simply altering chemokine cellular secretion 
mechanisms and that additional mechanisms of control must 
be involved. To provide further confidence in this effect, we 
then examined if the overexpression of CatS could induce 
CCL2 expression levels. MC38 cells were transfected with 
constructs encoding murine CatS (CatS) or an inactive 
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Figure 1: CatS ablation reduces tumour growth and macrophage recruitment. MC38 and LLC cells were stably transduced 
with lentiviral vectors expressing non-targeting (NT) control or CatS targeting shRNA sequences. a. MC38 NT control and CatS shRNA 
expressing cells were implanted into wild-type mice, with tumour growth was monitored and recorded as indicated. b. LLC NT control 
and CatS shRNA expressing cells were implanted into wild-type mice, with tumour growth monitored and recorded as indicated. c. LLC 
tumours were harvested 10 days post-implantation and subjected to flow cytometry to ascertain the number of F4/80+ cells. All in vivo 
experiments are indicative of 12 tumours, with data representative of the mean ± SEM. d. Raw264.7 cell migration was examined in 
response to tumour conditioned media from MC38 NT control and CatS shRNA cells (n = 3). e. Raw264.7 cell migration was also examined 
in response to tumour conditioned media from LLC NT control and CatS shRNA cells (n = 3). f. NIH3T3 fibroblast migration was examined 
in response to conditioned media from MC38 NT control and CatS shRNA expressing cells (n = 3). All data is representative of the mean 
± SEM.
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mutant version where the catalytic cysteine residue was 
mutated to a serine residue (CatS C/S) (Supplementary Fig. 
4). Analysis of CCL2 by ELISA showed that CatS had the 
ability to induce CCL2 expression and this was dependent 
upon the catalytic activity of the protease, given that 
overexpression of CatS C/S had no apparent effect (Fig. 3e). 
Taken together, this data would suggest that CatS can control 
CCL2 expression within different tumour cell types and that 
proteolytic activity of the protease is important in mediating 
this effect.
CatS regulation of CCL2 attenuates macrophage 
migration
One of the predominant roles of CCL2 is the 
recruitment of monocytes/macrophages in a plethora of 
inflammatory diseases, including cancer [16]. To verify 
the importance of the CatS-CCL2 axis, macrophage 
migration assays were also performed in the presence of 
a CCL2 antagonistic antibody. In MC38 non-targeting 
control conditioned media, there was a dose-dependent 
decrease in macrophage migration in the presence of 
the antagonistic antibody, which was comparable to the 
impact of conditioned media from MC38 CatS shRNA 
cells (Fig. 4a).
In order to confirm the impact of CatS on 
macrophage migration, B16 melanoma cells, which lack 
CCL2, were utilised and verified by ELISA (Fig. 4b). B16 
stable cells lines expressing CatS shRNA constructs were 
established (Fig. 4c) and migration assays were performed 
using conditioned media harvested from these cells. 
Despite CatS levels being substantially reduced by the 
shRNA sequences, B16 conditioned media had no effect on 
macrophage migration, irrespective of the CatS status of 
Figure 2: Pro-inflammatory chemokine expression levels are altered in the absence of CatS. MC38 NT control cells 
were implanted in wild-type mice, with CatS shRNA expressing cells implanted into CatS−/− mice in order to identify changes in protein 
expression due to diminished CatS expression. Tumours and serum were extracted 12 days after implantation. a. Interrogation of tumour 
lysates by antibody array, identified altered expression of CXCL10, CXCL1 and CCL2 (highlighted by the dashed boxes from left to 
right). b. Densitometry analysis of antibody arrays enabled quantification of expression changes of CXCL10, CXCL1 and CCL2. c. Serum 
samples were also interrogated by antibody array to determine changes based on CatS expression status. d. Densitometry analysis enabled 
quantification of the changes in CCL2 expression, made relative to mice bearing the control tumours.
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Figure 3: CCL2 expression is correlated with CatS. CCL2 expression was measured by ELISA in a. MC38 cell lysates, b. MC38 
supernatants, c. LLC cell lysates and d. LLC supernatants. e. Transient overexpression of CatS in MC38 cells led to the significant induction 
of CCL2 expression, whereas overexpression of catalytically inactive CatS (CatS C/S) had no impact on CCL2 when measured by ELISA. 
All experiments are representative of n = 3 and data is representative of the mean ± SEM.
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the cells (Fig. 4d). These findings therefore further confirm 
the association between CatS and CCL2 is important for 
macrophage migration.
CatS transcriptionally regulates CCL2 
expression
Having evaluated CCL2 depletion in colon and 
lung carcinoma cell lines and determined that CCL2 
expression levels were regulated both intracellularly and 
extracellularly, we wanted to examine in more detail how 
CatS was regulating CCL2. Using MC38 and LLC shRNA 
cell lines, we assessed expression of CCL2 by RT-PCR 
and determined that CCL2 was transcriptionally regulated 
by CatS (Fig. 5a, 5b). Furthermore, these findings were 
confirmed by transfecting MC38 cells with a luciferase 
construct encoding the CCL2 promoter region. Luciferase 
activity was significantly attenuated in cells expressing 
the CatS shRNA compared to the non-targeting control 
cells (Fig. 5c). Collectively, these experiments confirmed 
that CatS has the ability to function as a transcriptional 
regulator of CCL2 expression.
CatS regulates CCL2 expression by modulation 
of CD74 processing
Previous studies have implicated the cell surface 
transmembrane protein CD74 in the regulation of pro-
inflammatory chemokines, such as CCL2. Proteolytic 
cleavage of an intracellular domain fragment (ICD) 
enables its translocation to the cell nucleus where it 
promotes NFkB activity [17]. CD74 has been well 
documented as a chaperone that facilitates stability of the 
MHC-II heterodimer, which can be cleaved by CatS prior 
Figure 4: CatS regulation of CCL2 is responsible for altered macrophage recruitment. a. Raw264.7 cell migration was 
examined using tumour cell conditioned media from MC38 NT control (NT) and CatS shRNA (CatS) expressing cells. NT control 
conditioned media was also incubated with an antagonistic CCL2 antibody to verify the impact of CCL2 on cell migration. b. The lack 
of CCL2 expression in B16-F10 cells, was verified by ELISA, in comparison to other cell lines utilized in this work. c. B16-F10 cells 
were engineered to stably express the NT control and CatS shRNA constructs and knockdown of CatS expression was verified by RT-
PCR. GAPDH amplification was used as an internal control to ensure equal loading. d. Raw264.7 cell migration using conditioned media 
harvested from B16-F10 NT control and CatS shRNA expressing cells was ascertained. All experiments are representative of n = 3 and 
data is representative of the mean ± SEM.
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to antigen presentation [18]. To interrogate a link between 
CatS, CCL2 and CD74, MC38 cells were treated with an 
agonistic CD74 antibody. Previous studies have identified 
that the activation of CD74 with this antibody results in 
the induction of cell proliferation [19]. Our results show 
that cells expressing CatS display increased proliferation 
when treated with the agonistic CD74 antibody, whereas 
there was no effect on cells lacking CatS (Fig. 6a). 
Likewise, when CD74 expression was depleted by 
shRNA (Supplementary Fig. 5), the agonistic antibody 
had no effect (Fig. 6a). In a similar manner, cells treated 
with the CD74 ligand MIF, also displayed an increase in 
proliferation compared to cells depleted in either CatS 
or CD74 (Fig. 6b). Furthermore, given the association 
between CCL2 expression and NFkB activity, luciferase 
assays were performed using an NFkB reporter construct 
transfected into MC38 cell lines. Cells expressing CatS 
shRNA sequences displayed significantly reduced NFkB 
activity in comparison to the non-targeting control 
expressing cells (Fig. 6c).
To further examine the role of CD74 in CatS 
regulation of CCL2, MC38 cells were transfected with 
CD74 expression constructs encoding the full-length 
transmembrane (CD74-FL) and intracellular domain 
(CD74-ICD, which lacks the transmembrane and 
endosomal domains) proteins (Supplementary Fig. 6). We 
hypothesized that overexpression of CD74-FL in CatS 
depleted cells would have no impact on CCL2 expression 
level as the protease was not present  to facilitate 
the cleavage and promote release of CD74-ICD. 
Indeed we found that the reduced CCL2 production 
caused by depletion in CatS was unable to be rescued 
by over-expression of the CD74-FL protein. However, 
the over-expression of the CD74-ICD did induce a 
Figure 5: CatS can transcriptionally regulate CCL2 expression. RT-PCR analysis of CCL2 expression in a. MC38 and b. LLC 
cells expressing CatS shRNA constructs, with GAPDH amplification used as an internal control. c. MC38 cells were transiently transfected 
with a CCL2 promoter construct containing a luciferase reporter element. Luciferase activity was measured 24 hrs following transfection 
using the Dual-Glo® luciferase assay system. All experiments are representative of n = 3 and data is representative of the mean ± SEM.
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Figure 6: CatS regulation of CCL2 is mediated by CD74. MTT assay was used to measure cell viability, following treatment 
of MC38 cells with a. CD74 agonistic antibody, or b. CD74 ligand, MIF. Absorbance was measured at 570 nm and results expressed 
relative to the untreated control. c. Transient transfection of a NFkB luciferase construct in MC38 cells. Luciferase activity was measured 
24 hrs following transfection using the Dual-Glo® luciferase assay system. d. The impact of transient overexpression of full length CD74 
(CD74-FL) and CD74 intracellular domain (CD74-ICD) on CCL2 expression in MC38 cells was determined by ELISA. e. MC38 cells were 
examined for alterations in CCL2 production by ELISA due to expression of the CatS shRNA, following treatment with DAPT, or both in 
combination. All experiments are representative of n = 3 and data is representative of the mean ± SEM.
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significant increase in CCL2 expression, demonstrating 
that its activity is independent of CatS and in keeping 
with previous reports that it can constitutively interact 
with NFkB, requiring no endosomal processing (Fig. 6d).
Previous studies has also implicated the multimeric 
protein complex, gamma secretase, with the proteolytic 
release of the CD74-ICD fragment, following CatS 
cleavage of the endosomal domain of CD74. Here, we 
have shown that in MC38 colon carcinoma cells, targeting 
of CatS (using shRNA) or gamma secretase (using DAPT), 
results in the attenuation of CCL2 protein expression, in 
agreement with previous observations [20, 21]. However, 
our results have also shown that the greatest impact on 
CCL2 expression appears to be mediated via depletion of 
CatS, with an enhanced effect observed when combined 
with gamma secretase inhibition using DAPT (Fig. 6e). 
Collectively, these findings would suggest that the gamma 
secretase cleavage does occur downstream of the CatS 
cleavage event.
CCL2 expression is a potential biomarker for 
CatS activity
Finally, we wanted to investigate the significance of 
these findings through the examination of clinical material. 
A number of publically available gene array datasets were 
studied in order to delineate the clinical relationship 
between CatS and CCL2. Analysis was performed using a 
range of human tumour types (colorectal, breast and brain 
carcinomas) and a significant correlation between CatS 
and CCL2 expression was observed in all tumour datasets 
examined (Fig. 7a–7c). In our previous work, we have 
documented an association between CatS expression and 
patient survival in both brain and colorectal carcinomas, 
both of which identified CatS as a poor prognostic marker 
[7, 22]. Studies have also proposed CCL2 as a poor 
prognostic marker in multiple different tumour types, in 
particular breast cancer [23, 24]. Using CatS selective 
small molecule inhibitor compound 6 (Merck-Frosst) 
[25] (Supplementary Fig. 7), we have demonstrated a 
significant dose-dependent reduction in CCL2 expression 
following treatment with the inhibitor, adding further 
support to our hypothesis that CCL2 is a potential 
biomarker of CatS activity (Fig. 7d).
DISCUSSION
CatS has been implicated in the regulation of 
tumourigenesis by facilitating invasion and angiogenesis 
[5, 6, 13]. Numerous studies have also shown that CatS 
has a significant correlation with other inflammatory 
diseases. Given the inherently inflammatory nature of 
tumours, we wanted to investigate the mechanisms by 
which this protease contributes to tumourigenesis. This 
work details for the first time the potential for CatS to 
function as a transcriptional mediator of gene expression. 
Whilst previous publications have documented roles for 
CatS in tumourigenesis, there has been little evidence 
to support specific mechanisms by which the protease 
mediates the disease. The main findings from our studies 
are that tumour-derived CatS can transcriptionally 
regulate the pro-inflammatory chemokine CCL2, in 
a CD74-dependent manner and influence the tumour 
microenvironment, by altering cellular recruitment of 
macrophages. As such, this work opens up a plethora 
of potential novel roles for not only this protease, but 
other cathepsin family members also, in the mechanistic 
regulation of disease.
The role of CCL2 as a potent regulator of monocyte/
macrophage recruitment has been well documented 
[26–28]. Eloquent work by Qian et al, identified CCL2 
as a major mediator of inflammatory monocyte recruitment 
in breast cancer metastasis and how a specific subtype of 
macrophages, termed metastasis associated macrophages 
(MAMs) are preferentially recruited to pulmonary 
metastasis [24]. Further studies have also implicated 
CCL2 with roles in multiple inflammatory diseases such 
as Alzheimer’s Disease [29], Multiple Sclerosis [30] and 
pulmonary fibrosis [31]. Given the association of both 
CatS and CCL2 in a plethora of inflammatory diseases, 
we believe that CCL2 may have potential to act as a 
biomarker for CatS activity in clinical material, given 
the close correlation in their expression in our clinical 
sample analysis and preliminary experiments with CatS 
targeting compounds. The development of therapeutic 
targeting strategies towards CatS is of particular interest 
to numerous drug companies and several clinical trials 
are currently underway evaluating the efficacy of such 
compounds in diseases such as rheumatoid arthritis, 
neuropathic pain and psoriasis [32].
This work has delineated that CatS-mediated 
transcriptional regulation of CCL2, is facilitated, at least 
in part, through known CatS substrate, CD74. CD74 is 
a type 1 transmembrane glycoprotein, primarily known 
for its role as the invariant chain in MHC-II antigen 
presentation. CatS has been previously implicated with 
CD74 processing through the mediation of MHC-II 
antigen presentation, where CD74 cleavage is essential 
for maintaining stability of the MHC-II heterodimer and 
facilitating peptide loading [18, 33]. CD74 and its ligand, 
MIF (macrophage migration inhibitory factor) have 
previously been implicated in inflammatory diseases [34].
Studies by the Shachar group have extensively 
examined CD74 and have identified that it is a member 
of the regulated intramembrane proteolysis (RIP) protein 
family, with sequential proteolytic cleavage of CD74 
resulting in the liberation of the CD74 intracellular 
domain (CD74-ICD), which can initiate NFkB activation 
and CCL2 expression (as illustrated in Fig. 8). Further 
research suggested that CatS mediated cleavage of 
CD74 is required prior to the intramembrane release of 
the ICD by gamma secretase; inhibition of CatS with a 
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small-molecule inhibitor results in the accumulation of 
CD74 intermediate fragments and prevents the release of 
CD74-ICD. Furthermore, deletion of the luminal domain 
of CD74 (which contains the CatS cleavage site), enables 
more efficient release of the ICD fragment. Collectively 
this indicates that CatS must cleave the luminal domain of 
CD74 first in order for release of the ICD to be mediated 
by gamma secretase [22]. Our results presented here are 
consistent with this previous research, but clearly other 
mechanisms for modulation of CCL2 are likely to exist.
Whilst previous studies have associated CatS 
expression with tumour infiltrating macrophages 
[8, 11, 12, 35], there has been limited work to identify 
the mechanistic involvement of this protease in mediating 
tumourigenesis. Recent work by Shi et al, has identified 
a reduction in macrophage recruitment using CatS null 
mice in neointimal hyperplasia studies [36]. This work 
is in agreement with our observations that CatS can 
regulate macrophage recruitment towards inflammatory 
areas in disease, but we believe that we have added to this 
recent work through the identification of CCL2 as a key 
chemokine involved in the process, determining that CatS 
mediates this effect through the transcriptional regulation 
of CCL2.
With regards to our novel observations on the impact 
of CatS on fibroblast migration, the mechanistic regulation 
of this observation is largely unknown. Historically, there 
has been little evidence to associate CatS with fibroblasts, 
but recent studies have suggested that CatS plays an 
important role in mediating fibroblast transdifferentiation 
in myocardial infarctions [15]. Our observations that 
CatS deregulates several reported fibroblast chemokines 
warrants further investigation in order to dissect the 
mechanism behind these findings.
Collectively, the work outlined in this study provides 
novel evidence for mechanistic roles of CatS in diseases 
such as cancer. We hypothesize that other inflammatory 
based disorders such as cardiovascular disease, may also 
exhibit similar mechanisms in relation to CatS function. 
Previous work has suggested that proteases such as CatS 
can mediate processing of chemokine function in order 
to regulate their activity [37], but this work shows for 
the first time that CatS can function as a transcriptional 
regulator of protein expression. CCL2 could be a potential 
Figure 7: CatS and CCL2 expression are correlated in human tumour samples. Gene array analysis examining the correlation 
between CatS and CCL2 in human tumour datasets representing a. colorectal, b. breast and c. brain tumours. d. MC38 cells were treated 
with an increasing concentration of CatS inhibitor 6 and the impact on CCL2 expression in the supernatants was measured by ELISA. 
Experiments are representative of n = 3 and data is representative of the mean ± SEM. PC: Pearson coefficient, SR: Spearman rank.
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biomarker for CatS activity in disease, it is likely that 
other factors may also exist but these would require further 
in depth analysis. Together, these findings reinforce the 
rational for understanding the mechanistic role of these 
proteases in disease when considering them as therapeutic 
targets.
MATERIALS AND METHODS
Cell culture experiments
293T human embryonic kidney cells (ATCC), 
NIH-3T3 fibroblasts (ATCC), MC38 colon 
adenocarcinoma cells (S Rosenberg, NCI), B16-F10 
murine melanoma cells (ATCC) and RAW 264.7 
leukaemic monocyte macrophage cells (ATCC) were 
cultured using DMEM supplemented with 10% FBS (Life 
Technologies, UK), 100 μg/ml penicillin and 100 μg/ml 
streptomycin (Life Technologies, UK). The Lewis lung 
carcinoma line (LLC) (ATCC) was cultured using RPMI 
1640 (Life Technologies, UK) supplemented with 10% 
FBS (Life Technologies, UK), 100 μg/ml penicillin and 
100 μg/ml streptomycin (Life Technologies, UK). All cells 
were maintained in a humidified environment containing 
5% CO
2
 at 37°C. Experiments within which cells were 
treated with the gamma secretase inhibitor DAPT (Tocris), 
cells were seeded in 96 well plates and treated with 50 μM 
DAPT for 5 hours, prior to collection of cell supernatants 
for downstream analysis.
Lentiviral generation of stable shRNA lines
CatS targeting shRNA constructs and non-targeting 
controls within the pLKO.1 plasmid were purchased, 
alongside the packaging plasmid mix for lentiviral 
transduction (Sigma Aldrich, UK). Viral particles were 
produced by transfection of the constructs into the 293T 
packaging cell line using GeneJuice (Merck Millipore, 
UK). After 48 hrs, viral supernatants were collected, 
filtered through 0.45 μm filters and supplemented with 
6 μg/ml PolyBrene (Sigma Aldrich, UK) before being 
applied to the cells of interest for 4 hrs. Following this, the 
Figure 8: Proposed mechanism of action for CatS mediated regulation of CCL2 via CD74. CD74 is internalized within 
endocytic vesicles, where the extracellular domain resides within the vesicle and the intracellular domain (CD74-ICD) extends into the 
cytoplasm. CatS within the endocytic vesicle has been proposed as a key protease responsible for the cleavage of the CD74 within the 
endosome (green scissors), whereas gamma secretase has been implicated in regulated intramembrane proteolysis of the transmembrane 
domain of CD74 resulting in liberation of CD74-ICD (blue scissors). Released CD74-ICD can translocate and interact with NFkB in the 
nucleus where it regulates the expression of chemokines such as CCL2. Adapted from Martín-Ventura, J.L. et al [20].
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lentiviral particle solution was removed from the cells and 
replaced with fresh full media for 24 hrs before selection 
of a stable cell line in puromycin. Successful diminution 
of CatS expression was verified by RT-PCR.
Reverse transcriptase-PCR
RNA was extracted from cell lines using STAT60 
(Biogenesis, UK) according to manufacturers instructions. 
mRNA was converted to cDNA using the ImProm-II 
Reverse Transcriptase system (Promega, UK) and target 
sequences were amplified by conventional PCR using 
RedTaq (Sigma Aldrich, UK) with gene specific primers. 
All PCR products were visualized using agarose gel 
electrophoresis on a 1% gel.
In vivo experiments
All mice used in these experiments were aged 
between 8 and 12 weeks with housing and experimentation 
carried out in accordance with the Animal (Scientific 
Procedures) Act 1986, following current UKCCCR 
guidelines and approved by the Ethical Review Committee 
within Queen’s University Belfast. C57BL/6 mice were 
purchased from Charles Rivers Laboratories and CatS−/− 
mice were obtained from J. A. Joyce, Memorial Sloan 
Kettering Cancer Center, New York with permission from 
H Chapman, UCSF. Mice were subcutaneously injected 
with 5 × 105 MC38 or LLC cells mixed with reduced 
growth factor Matrigel (final concentration: 4 mg/ml) (BD 
Biosciences, UK). Tumor volumes were calculated with 
digital calipers, using the formula, V = a × b2 × π/6, with 
a and b representing the longer and shorter diameter of the 
tumor, respectively. Data was presented as mean tumor 
burden (mm3) per group ± SEM.
Flow cytometry
Flow cytometry experiments were performed 
as previously described [8]. Briefly, tumors were 
disaggregated and digested in 0.125% trypsin for 20 min 
at 37°C. The resultant cell suspension was filtered through 
a nylon mesh (BD Biosciences, UK) to remove debris, 
washed, centrifuged and resuspended in sterile PBS. Cells 
were blocked on ice for 10 min using Mouse BD Fc block 
(BD Biosciences, UK) and then stained using anti-mouse 
F4/80 conjugated to PE-Cy7 (EBioscience, UK) and anti-
mouse CD11b conjugated to APC (BD Biosciences, UK). 
Flow cytometry was performed with a BD FacsAria II 
with FacsDiva software and data analysis was performed 
using Flowjo.
Migration assays
Raw264.7 and NIH3T3 cells were analysed for 
their ability to migrate through 8.0 μm transwell inserts 
(Corning, USA). Cells were resuspended to 5 × 105/ml in 
serum free media with 200 μl added to the inner chamber 
of each transwell insert. Conditioned media from the 
appropriate cell line (700 μl) was added to the lower 
chamber to act as a chemoattractant and cells were 
incubated at 37°C with 5% CO
2
 for 16 hrs. Non-migrated 
cells were removed and migrated cells were fixed in 
Carnoy’s fixative for 15 mins. After drying, the nuclei 
of the migrated cells were stained with Hoechst 33258 
(50 ng/mL) in PBS for 30 mins at room temperature. The 
chamber insert was washed twice in PBS and mounted 
in Citifluor, and migrated cells were viewed and counted 
with a Nikon Eclipse TE300 fluorescent microscope. All 
assays were done in triplicate and 10 digital images of 
representative fields from each of the triplicate membranes 
were taken using a Nikon DXM1200 digital camera at 
magnification of x20. Results were analyzed using Lucia 
GF 4.60 software by Laboratory Imaging and expressed 
as the average number of migrated cells per field of 
view (±SEM).
Antibody array
Tumour lysates were prepared using RIPA buffer 
(Sigma-Aldrich, UK) and serum samples were extracted 
from MC38 tumour bearing mice for analysis using 
Proteome Profiler Antibody arrays (R&D Systems, 
UK). Arrays were performed according to manufactures 
instructions and were visualized and quantified by 
chemiluminescence using the ChemiDoc XRS imaging 
system (Bio-Rad Laboratories).
ELISA
Murine CCL2 ELISAs (R&D Systems, UK) were 
performed on tumour lysates and supernatants according 
to manufactures instructions. Briefly, maxisorb 96 well 
plates were coated with anti-CCL2 capture antibody 
overnight at room temperature. Plates were washed in 
PBS-T and blocked in 1% BSA in PBS for 1 hr prior to 
incubation with the protein sample at room temperature 
for 2 hrs. Following washing, plates were incubated with 
the murine CCL2 detection antibody, washed and then 
incubated with streptavidin-HRP. Following the final 
wash steps, wells were incubated with the chromogenic 
substrate tetramethylbenzidine (Calbiochem) for 10 min 
at room temperature. The reaction was stopped by the 
addition of 500 mM HCl and absorbance was read 
at 450 nm.
Transfections
All transfections were performed using Genejuice 
(Merck Millipore, UK) according to manufactures 
instructions. Briefly, cells were seeded and transfected 
with murine CatS, CatS C/S, CD74-FL or CD74-ICD 
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expression constructs. 48 hrs following transfection, cells 
were harvested for subsequent analysis. CatS constructs 
had been cloned into pcDNA3.1 incorporating a 
C-terminal Flag tag, whilst CD74 constructs were a kind 
gift from Professor Idit Shachar (Weizman Institute, Israel) 
and were also sub-cloned into pcDNA3.1 to incorporate 
a C-terminal Flag tag. The catalytic cysteine residue of 
pcDNA3.1 CatS was mutated to a serine reside using site 
directed mutagenesis (Agilent Technologies, USA) to give 
rise to the CatS C/S construct.
Luciferase assays
Cells were seeded in 6-well plates and transfected 
with a pGL3 NFkB reporter, Renilla, CCL2 promoter 
or control plasmid using Genejuice (Merck Millipore, 
UK) according to manufactures instructions. Cells were 
incubated for 24 hrs following transfection before lysis 
with passive lysis buffer and luciferase activity was 
determined using Dual-Glo® luciferase assay system 
(Promega, UK) as per manufactures instructions. All 
experiments were repeated in triplicate a minimum 
of three times. pGL3 based constructs were a kind gift 
from Dr Niamh Buckley (Centre for Cancer Research 
and Cell Biology, Queen’s University Belfast) and the 
CCL2 luciferase promoter construct was purchased from 
Addgene (Addgene, USA).
MTT assay
Cell proliferation following treatment with 
anti-CD74 agonistic antibody (Santa Cruz, USA) or mMIF 
recombinant protein (R&D Systems, UK) was assessed 
by MTT assay. Cells were seeded at 1 × 104 per well of a 
96-well plate in 200 μl of cell growth medium. Cells were 
treated with the agonistic antibody (2.5 μg/ml) or MIF 
protein (2.5 ng/ml) and incubated at 37°C with 5% CO
2
 
for 24 hrs. Cells were incubated with 20 μl of 10 mg/ml 
MTT and returned to the incubator for a further 3 hrs. The 
media and MTT mixture was carefully removed and the 
insoluble formazan crystals were dissolved in 50 μl/well 
of DMSO. Absorbance was measured at 570 nm and the 
results were expressed as the percentage cell number 
relative to the untreated control. All tests were done in 
quintuplicate.
Co-expression analysis of CCL2 and CTSS
Publically available microarray datasets were 
obtained from gene expression omnibus (GEO) containing 
clinical expression profiles in colorectal (GSE17537), 
breast (GSE12276) and brain (GSE4271) cancers. Data 
was transformed into Log2 expression and individual 
probe sets corresponding to desired gene sets identified. 
For each gene of interest, a median value of expression 
intensity was obtained from each gene probe set. Gene 
co-expression was analysed using ‘R’ statistical software 
program and correlation was evaluated by Pearson 
coefficient (PC) and Spearman Rank (SR).
Statistical analysis
Within these experiments, results have been plotted 
using Prism software (GraphPad, USA) and errors bars 
have been plotted as the standard error of the mean 
(SEM). The Student’s t test has been used to determine 
the statistical significance between the different samples.
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